Warfarin PSD/HOF001/GB/DC/Rev013 Issued : 24.03.2016 Review interval:12 months This document may be reviewed and reissued electronically without notice.

Slides:



Advertisements
Similar presentations
Educational Event 23rd & 24th January 2013
Advertisements

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Atrial Fibrillation Service
National Adult Clozapine Titration Chart
Audit of warfarin reversal in over-anticoagulated patients D Wright and J Seal Department of Haematology Pontefract General Infirmary Nov 2002.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Prophylaxis of Venous Thromboembolism
DR DIPTI CHITNAVIS HAEMATOLOGY CONSULTANT WEST SUFFOLK HOSPITAL JANUARY 2014 Update on the new oral anticoagulants; 12 months on.
Stroke prevention in atrial fibrillation
Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
AF and NOACs An UPDATE JULY 2014
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Improving Stroke Prevention in Patients With Atrial Fibrillation.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Management of A.F. patients with the DawnAC induction module David Hirst MidYorkshire Hospitals NHS Trust.
Atrial Fibrillation Warfarin and its newer alternatives
WARFARIN AN OVERVIEW.
Vanderbilt Pediatric Hematology Anticoagulation Guidance Protocol Robert F. Sidonio, Jr. MD, MSc. 4/12/12 Warfarin Monitoring If inpatient, consider monitoring.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
Annual Report 2003 Power Point Presentation. Mechanics of merging data.
VTE prevention and anticoagulation practice VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis Nurse RCHT.
Clopidogrel Audit Vikas Jasoria December What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.
ALI R. RAHIMI, BOBBY WRIGHTS, MD, HOSSEIN AKHONDI, MD & CHRISTIAN M. RICHARD, MSC Clinical Correlation Between Effective Anticoagulants & Risk of Stroke:
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
April 09 – September 09  10,245 daily newsletter recipients  18,798,938 pages accessed by users  3,565,340 news items read by users  38,039 records.
Anticoagulants Reducing the risk Amanda Powell & Sue Wooller May 2014.
By the end of this session you should:
Mandatory Training: VTE prevention and anticoagulation practice Mandatory Training: VTE prevention and anticoagulation practice Mr A McSorley Lead Thrombosis.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
CV Update – Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet – 27/01/09 Dr Ameet Bakhai, FRCP – Cardiologist, Clinical Trials, Health.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.
CHADS, SHMADS: What’s All This About Anticoagulation? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.
Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE (STAC) PATIENT SPECIFIC DIRECTION FOR DALTEPARIN (LMWH) FOR PATIENTS WITH VENOUS THROMBO-EMBOLISM (VTE)/MECHANICAL.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Outpatient DVT assessment & treatment Daniel Gilada.
ANTICOAGULATION The objectives of this section are: To be able to write prescriptions according to local anticoagulation guidelines To know how to prescribe.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
The VERITY Steering Committee
Copyright © 2012 American Medical Association. All rights reserved.
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Antithrombotic Therapy in Atrial Fibrillation
Anticoagulants in the Treatment of Venous Thromboembolism
No evidence that AF type significantly impacts stroke risk
Introduction Welcome to this training module for the HSC Medicine Prescription and Administration Record 8 week kardex , commonly referred to as the ‘Long.
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Aug, 2016.
Selecting NOACs for High-Risk Patients
Bridging Anticoagulation
Presentation transcript:

Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice. You should regularly check the UHNM intranet to ensure that you are using the most up to date revision. All hard copies of this document should be considered to be uncontrolled STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE PATIENT SPECIFIC DIRECTION FOR WARFARIN Patient Details Surname Forename(s) Unit Number/NHS No Date of Birth Address/contact number M/FEthnicity Referrer Details Name and Position Location for first visit (tick as appropriate including ward) InpatientOutpatient GP/Consultant Name GP/Consultant contact details Please initiate and monitor warfarin for this patient for a duration of ………………. months/indefinite with an INR target of ……………………………. The indication for oral anticoagulation and the date of diagnosis: …………………………………………………………………………………………………………………………………………………………………………………………. If applicable, the CHADS/CHA 2 DS 2 Vasc score of the patient is …………………………(please see guidance notes page 3). Pending investigations and date referred:…………………………………………………………………………………………………………………………. Start warfarin as per the following algorithm: Rapid (Fennerty) / Slow (Tait) – tick as appropriate on page 2. UHNM ONLY : For patients with an acute venous thromboembolism or mechanical heart valve please also complete dalteparin referral form. Continue monitoring of INR and advise patient of warfarin dose change as per the validated computerised algorithm (DAWN) Supply the patient, 28 tablets of each strength of warfarin 1mg tablets, 3mg tablets and 5mg tablets. By completing this form and signing below, I confirm the following : 1. I am aware that this anticoagulation service will hold clinical responsibility for the anticoagulation of my patient. 2. I confirm that the patient is aware of the indication, benefits and side effects of oral anticoagulation and does not have any contra-indications for anticoagulation. Signature………………………………………….Name (please print): …………………………………………… ( Only Consultant/GP/Registrar/Non-medical prescriber to sign) Date: …………………………………………….. DateINRWarfarin dose (Five most recent results & dose) If already on warfarin enter recent INR and dose record Page 1 of 3 INCOMPLETE REFERRALS WILL NOT BE ACCEPTED Current Medication (please specify Anti-platelet drugs and other interacting medication) To continue when INR is therapeutic Y/N Aspirin …..…….. mg daily Clopidogrel ……….mg daily please fax recent prescription with the form

STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE PATIENT SPECIFIC DIRECTION FOR WARFARIN Patient Name:Unit Number: Date of Birth FENNERTY 1 (PE, DVT where rapid anticoagulation is desirable) Tick Day 1 INR ≤ mg Day 2 INR <1.810mg mg >1.80.5mg Day 3 INR <2.010mg 2.0 – 2.15mg 2.2 – mg 2.4 – 2.54mg 2.6 – mg 2.8 – 2.93mg 3.0 – mg 3.2 – 3.32mg mg 3.51mg 3.6 – mg Day 4 INR <1.4>8mg 1.48mg mg 1.6 – 1.77mg mg 1.96mg 2.0 – mg 2.2 – 2.35mg 2.4 – mg 2.7 – 3.04mg 3.1 – mg 3.6 – 4.03mg 4.1 – 4.50mit – 2mg from day 5 >4.5Omit for 2 days & 1mg from day 6 TAIT 2 (Slow anticoagulation) (FOR AF OR IN THE ABSENCE OF VTE) Tick Day 1 INR ≤ mg for 4 days Day 5 INR Dosage in mg for days Day 8 INR Dose in mg from day 8 ≤ 1.75mg≤ – – 3.0 >3.0 <5.0 >5.0 6mg 5mg 4mg 3mg for 4 days Omit until INR<5 1.8 – 2.24mg≤ – – – 3.5 >3.5<5 >5 5mg 4mg 3.5mg 3mg for 4 days 2.5mg for 4 days Omit until INR<5 2.3 – 2.73mg≤ – – – 3.5 >3.5<5 >5 4mg 3.5mg 3mg 2.5mg for 4 days 2mg for 4 days Omit until INR<5 2.8 – 3.22mg≤ – – – 3.5 >3.5<5 >5 3mg 2.5mg 2mg 1.5mg for 4 days 1mg for 4 days Omit until INR<5 3.3 – 3.71mg≤ – – – 3.5 >3.5 2mg 1.5mg 1mg 0.5mg for 4 days Omit for 4 days ≥ 3.70mg< – – mg for 4 days 1mg for 4 days 0.5mg for 4 days Page 2 of 3 Warfarin PSD/HOF001/GB/DC/Rev013 Issued: Review interval:12 months This document may be reviewed and reissued electronically without notice. You should regularly check the UHNS intranet to ensure that you are using the most up to date revision. All hard copies of this document should be considered to be uncontrolled 1.British Medical Journal, 1984; 288, British J of Haematology, 1998; 101, Complete all pages of this form and send via FAX or as attachment to secure All requests will be acknowledged within 24hrs FAX No: (9.00am-4.30pm, Mon-Fri) Tel: Additional copies of this form can be obtained from lServices/Anticoagulantmanagementservice.aspx lServices/Anticoagulantmanagementservice.aspx

Warfarin PSD/HOF001/GB/DC/Rev013 Issued Review interval:12 months This document may be reviewed and reissued electronically without notice. You should regularly check the UHNS intranet to ensure that you are using the most up to date revision. All hard copies of this document should be considered to be uncontrolled Indication for Oral Anticoagulation 1 Target INR Duration of Treatment Termination Date Atrial Fibrillation (complete CHA 2 DS S -VASc table)2.5Indefinite Proximal DVT/PE (provoked)2.53 months Proximal DVT/ PE (unprovoked/spontaneous) (patients with cancer associated DVT/PE should receive LMWH) months consider long-term Isolated Distal vein Thrombosis2.56weeks Mechanical heart valve Aortic bileaflet2.5Indefinite Mechanical heart valve Mitral/ Aortic (please specify)3.5Indefinite Bio-prosthetic tissue valve Aortic/Mitral (please specify)2.53 months Cardiomyopathy2.5Indefinite Unprovoked Recurrent VTE (after stopping anticoagulation)2.5Indefinite Unprovoked Recurrent VTE (on therapeutic anticoagulation)3.5Indefinite Other (please specify) STAFFORDSHIRE THROMBOSIS AND ANTICOAGULATION CENTRE GUIDANCE FOR PRESCRIBERS Please complete and save this page in patient records CHA 2 DS 2 VASc Score for AF patients, to ensure the patient is suitable for warfarin Risk FactorYes/NoScore (C) Congestive Heart Failure/ Left Ventricular Dysfunction1 (H) Hypertension (> 160/90 or on anti-hypertensive drugs)1 (A 2 ) Age ≥752 (D) Diabetes Mellitus1 (S 2 ) Stroke/TIA/TE (Thromboembolism)2 (V )Vascular Disease – Coronary Artery Disease/MI/Peripheral Artery Disease or Aortic Plaque 1 (A) Age (Sc) Sex category – Female Gender1 Risk Score: 1 Indications for Oral Anticoagulation: BCSH Guidelines, For further information, suggestions, feedback and complaints please contact The Manager Staffordshire Thrombosis and Anticoagulation Centre (STAC) West Buildings Tel: University Hospital of North MidlandsFor further information, guidance and copies of Newcastle Roadthis form ST4 6QG Page 3 of 3 Anticoagulantmanagementservice.aspx